Price (delayed)
$5.07
Market cap
$493.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.8
Enterprise value
$480.44M
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system
There are no recent dividends present for ALEC.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.